Notable ETF Inflow Detected - FVD, HSY, KR, BTI
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 27 2025
0mins
Source: NASDAQ.COM
FVD Share Price Analysis: FVD's share price is currently at $44.55, with a 52-week low of $40.07 and a high of $46.825; analyzing the price against the 200-day moving average can provide insights into its performance.
ETFs Trading Dynamics: Exchange traded funds (ETFs) function like stocks but involve trading 'units' that can be created or destroyed based on investor demand, impacting the underlying assets held within the ETFs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BTI
About BTI
British American Tobacco p.l.c. is a global multi-category consumer goods business company. The Company provides tobacco and nicotine products. Its segments include the United States, Asia Pacific Middle East and Africa, and Americas and Europe. Its product categories include Vapor, Heating Products (HPs), Modern Oral, Traditional Oral, and Combustible cigarettes. Vapor products are handheld, battery-powered devices that heat a liquid to produce an inhalable aerosol, known as vapor. HPs are devices that use heat to generate a nicotine-containing aerosol, which the user inhales. This category includes Tobacco Heated Products and Herbal Products for Heating (HPH). Modern Oral products are smoke-free oral nicotine products called nicotine pouches, designed for use in the mouth. Traditional oral products include snus and snuff. Its brands include Vuse, glo, Velo, Grizzly, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, Camel, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Charlotte's Web Secures Major Deal with British American Tobacco
- Debt-to-Equity Conversion: Charlotte's Web Holdings Inc has converted $55 million in debt into equity with British American Tobacco, eliminating a major liability and saving $3 million in annual interest, thereby improving its financial position and capital structure.
- New Capital Injection: British American Tobacco has invested $10 million in Charlotte's Web, providing fresh capital to support the company's strategic initiatives, which is expected to drive product innovation and market expansion.
- Revenue Growth Momentum: The company reported a 15.8% sequential revenue increase in Q4 2025, driven by direct-to-consumer sales and product diversification, indicating a strong rebound in market demand.
- Significant Cost Management: Charlotte's Web has reduced its SG&A expenses by 44.5% over the past two years, demonstrating effective cost control and positioning for future profitability, despite facing a net loss of $11.4 million.
See More
Charlotte's Web Joins CMMI Medicare Pilot Program, Strengthening Growth Prospects
- Financial Structure Optimization: Charlotte's Web's transaction with British American Tobacco converts approximately $54 million in convertible debentures, eliminating $3 million in annual interest expenses, thereby significantly improving financial health and enhancing shareholder equity.
- Healthcare Program Participation: As a CBD launch partner for the CMMI Medicare pilot, the company is set to provide CBD products to senior patients starting in April 2026, potentially opening new market opportunities for approximately 67 million Medicare beneficiaries.
- Regulatory Policy Progress: The advancement of the HEMP Act signals significant policy support for the CBD industry, expected to facilitate the legalization of full-spectrum CBD products, further enhancing Charlotte's Web's competitive position in the market.
- Product Innovation and Market Expansion: In 2025, the company launched Brightside™ low-dose THC gummies, diversifying its product portfolio and achieving a 4.7% year-over-year growth in direct-to-consumer sales, indicating strong market demand.
See More
Altria Faces Challenges in Tobacco Market
- Stock Performance Review: While Altria has historically achieved an annual return of 20%, its performance over the past decade has been lackluster due to declining smoking rates in the U.S., highlighting the vulnerability of its core business.
- Diversification Failures: Altria's investments in Cronos Group and Juul Labs have resulted in billions in losses, and its recent acquisition of NJOY faced a ban from the U.S. International Trade Commission due to patent infringement, exacerbating financial pressures.
- New Product Sales Growth: Despite the decline in its core business, Altria's On! oral nicotine pouches saw an 11% increase in sales to 177.8 million cans over the past year, but a drop in market share indicates competitive pressures, particularly from Philip Morris's Zyn.
- Future Earnings Outlook: Altria projects earnings per share growth of 2.5% to 5.5%, reaching $5.56 to $5.72 in 2026, and with a 6.3% dividend yield, it still presents some investment appeal despite the risks associated with its declining core business.
See More
Altria's Diversification Efforts Falter
- Core Business Decline: Altria has managed profit growth by raising cigarette prices, yet its 2025 revenue after excise taxes fell 1.5% to $20.1 billion, indicating a persistent decline in its core business and significant risks for future growth.
- New Product Market Competition: Altria's On! oral nicotine pouches saw an 11% shipment increase to 177.8 million cans over the past year, but a decline in market share in Q4 due to Zyn's promotions suggests limited market acceptance for new products.
- Shareholder Returns and Risks: Despite a roughly 50% stock price increase over the past two years, Altria's 2026 earnings per share target of $5.56 to $5.72, combined with a 6.3% dividend yield, highlights the challenges and uncertainties the company faces during its transition.
- Uncertain Industry Outlook: With smoking rates among young Americans continuing to decline, Altria's cigarette sales are almost certain to keep falling, and if the company cannot replace lost profits with new products, its long-term stock price will face downward pressure.
See More
Charlotte's Web Engages in Strategic Transaction with BAT
- Capital Structure Optimization: Charlotte's Web's transaction with BAT involves converting C$75.3 million of convertible debentures into common shares, which is expected to eliminate approximately $65 million in debt, enhancing liquidity and simplifying the capital structure.
- Enhanced Shareholder Equity: The transaction will result in BAT holding about 110 million common shares, representing 40% of the total equity, which not only removes a major liability but also provides funding support for the upcoming CMMI Medicare pilot program.
- Interest Burden Reduction: By converting the debenture, Charlotte's Web will avoid approximately $12 million in future interest expenses, further improving its financial position and providing operational funding flexibility.
- Strategic Investment Support: BAT's additional $10 million investment will be used to support the CMMI Medicare pilot program, demonstrating confidence in Charlotte's Web's strategic direction and laying the groundwork for future market expansion.
See More
Charlotte's Web Secures Strategic Investment from BAT
- Capital Structure Optimization: Charlotte's Web's transaction with BAT converts C$75.3 million of convertible debentures into common shares, expected to eliminate US$65 million in debt, significantly improving financial health and strengthening shareholder equity.
- Increased Liquidity: BAT's concurrent US$10 million investment through a private placement is anticipated to provide funding for the company's participation in the CMMI Medicare pilot program, enhancing operational flexibility and market competitiveness.
- Shareholder Approval: The company plans to hold a shareholder meeting on May 28, 2026, to seek approval for the transaction, ensuring smooth completion and further consolidating its market position.
- Strategic Investment Significance: This transaction not only eliminates a major liability but also avoids approximately US$12 million in future interest payments, reflecting BAT's support for Charlotte's Web's strategic direction and aiding the company's expansion in the medical channel.
See More
Charlotte's Web Secures Major Deal with British American Tobacco
- Debt-to-Equity Conversion: Charlotte's Web Holdings Inc has converted $55 million in debt into equity with British American Tobacco, eliminating a major liability and saving $3 million in annual interest, thereby improving its financial position and capital structure.
- New Capital Injection: British American Tobacco has invested $10 million in Charlotte's Web, providing fresh capital to support the company's strategic initiatives, which is expected to drive product innovation and market expansion.
- Revenue Growth Momentum: The company reported a 15.8% sequential revenue increase in Q4 2025, driven by direct-to-consumer sales and product diversification, indicating a strong rebound in market demand.
- Significant Cost Management: Charlotte's Web has reduced its SG&A expenses by 44.5% over the past two years, demonstrating effective cost control and positioning for future profitability, despite facing a net loss of $11.4 million.
See More
Charlotte's Web Joins CMMI Medicare Pilot Program, Strengthening Growth Prospects
- Financial Structure Optimization: Charlotte's Web's transaction with British American Tobacco converts approximately $54 million in convertible debentures, eliminating $3 million in annual interest expenses, thereby significantly improving financial health and enhancing shareholder equity.
- Healthcare Program Participation: As a CBD launch partner for the CMMI Medicare pilot, the company is set to provide CBD products to senior patients starting in April 2026, potentially opening new market opportunities for approximately 67 million Medicare beneficiaries.
- Regulatory Policy Progress: The advancement of the HEMP Act signals significant policy support for the CBD industry, expected to facilitate the legalization of full-spectrum CBD products, further enhancing Charlotte's Web's competitive position in the market.
- Product Innovation and Market Expansion: In 2025, the company launched Brightside™ low-dose THC gummies, diversifying its product portfolio and achieving a 4.7% year-over-year growth in direct-to-consumer sales, indicating strong market demand.
See More
Altria Faces Challenges in Tobacco Market
- Stock Performance Review: While Altria has historically achieved an annual return of 20%, its performance over the past decade has been lackluster due to declining smoking rates in the U.S., highlighting the vulnerability of its core business.
- Diversification Failures: Altria's investments in Cronos Group and Juul Labs have resulted in billions in losses, and its recent acquisition of NJOY faced a ban from the U.S. International Trade Commission due to patent infringement, exacerbating financial pressures.
- New Product Sales Growth: Despite the decline in its core business, Altria's On! oral nicotine pouches saw an 11% increase in sales to 177.8 million cans over the past year, but a drop in market share indicates competitive pressures, particularly from Philip Morris's Zyn.
- Future Earnings Outlook: Altria projects earnings per share growth of 2.5% to 5.5%, reaching $5.56 to $5.72 in 2026, and with a 6.3% dividend yield, it still presents some investment appeal despite the risks associated with its declining core business.
See More
Altria's Diversification Efforts Falter
- Core Business Decline: Altria has managed profit growth by raising cigarette prices, yet its 2025 revenue after excise taxes fell 1.5% to $20.1 billion, indicating a persistent decline in its core business and significant risks for future growth.
- New Product Market Competition: Altria's On! oral nicotine pouches saw an 11% shipment increase to 177.8 million cans over the past year, but a decline in market share in Q4 due to Zyn's promotions suggests limited market acceptance for new products.
- Shareholder Returns and Risks: Despite a roughly 50% stock price increase over the past two years, Altria's 2026 earnings per share target of $5.56 to $5.72, combined with a 6.3% dividend yield, highlights the challenges and uncertainties the company faces during its transition.
- Uncertain Industry Outlook: With smoking rates among young Americans continuing to decline, Altria's cigarette sales are almost certain to keep falling, and if the company cannot replace lost profits with new products, its long-term stock price will face downward pressure.
See More
Charlotte's Web Engages in Strategic Transaction with BAT
- Capital Structure Optimization: Charlotte's Web's transaction with BAT involves converting C$75.3 million of convertible debentures into common shares, which is expected to eliminate approximately $65 million in debt, enhancing liquidity and simplifying the capital structure.
- Enhanced Shareholder Equity: The transaction will result in BAT holding about 110 million common shares, representing 40% of the total equity, which not only removes a major liability but also provides funding support for the upcoming CMMI Medicare pilot program.
- Interest Burden Reduction: By converting the debenture, Charlotte's Web will avoid approximately $12 million in future interest expenses, further improving its financial position and providing operational funding flexibility.
- Strategic Investment Support: BAT's additional $10 million investment will be used to support the CMMI Medicare pilot program, demonstrating confidence in Charlotte's Web's strategic direction and laying the groundwork for future market expansion.
See More
Charlotte's Web Secures Strategic Investment from BAT
- Capital Structure Optimization: Charlotte's Web's transaction with BAT converts C$75.3 million of convertible debentures into common shares, expected to eliminate US$65 million in debt, significantly improving financial health and strengthening shareholder equity.
- Increased Liquidity: BAT's concurrent US$10 million investment through a private placement is anticipated to provide funding for the company's participation in the CMMI Medicare pilot program, enhancing operational flexibility and market competitiveness.
- Shareholder Approval: The company plans to hold a shareholder meeting on May 28, 2026, to seek approval for the transaction, ensuring smooth completion and further consolidating its market position.
- Strategic Investment Significance: This transaction not only eliminates a major liability but also avoids approximately US$12 million in future interest payments, reflecting BAT's support for Charlotte's Web's strategic direction and aiding the company's expansion in the medical channel.
See More
